Guardant Health

With the recent FDA approval of our groundbreaking Shield blood test, Guardant Health is growing rapidly! Our screening sales team is expanding, and we're looking for several account executives and associate account executives who are passionate about putting patients first. This is an exciting time to join our team, with positions available across the U.S.! ? Learn more and apply here:?https://bit.ly/4d5ieZp

Planning to join other advanced oncology practitioners at #JADPROLive, November 14-17? Visit booth #1025 to talk with our team of advanced practice providers about the latest innovations in cancer care. Additional details and registration: https://jadprolive.com

November is #LungCancerAwarenessMonth. Let’s come together to raise awareness about the importance of early detection, research, and patient support to help conquer #LungCancer, the leading cause of cancer deaths globally.

Recently, our co-CEOs?AmirAli Talasaz and Helmy Eltoukhy joined healthcare leaders at the Health Equity Forum 2024 to engage in a meaningful dialogue about the vital role of diagnostics innovations in advancing health equity and enhancing health outcomes for all. ? Catch the full discussion here: https://bit.ly/4ecip5E

We're proud to be featured on TIME's list of Best Inventions of 2024, with our Shield blood test recognized in the medical care category. Our co-CEO AmirAli Talasaz: “We’re honored to be a part of this prestigious list of leading innovative products that are making a dramatic difference in how we live our lives today. We created Guardant Health with the vision to detect and characterize cancer across the spectrum, and now we are able to do this with colorectal cancer at earlier stages with the launch of Shield. This has the opportunity to transform cancer detection and save millions of lives." #TIMEBestInventions2024

Join us for an upcoming online panel discussion focused on the transformative role of methylation-based ctDNA testing for minimal residual disease and response monitoring in clinical trials. Industry leaders?Minakshi Guha, Jonathan Beer, Diana Merino Vega,?and our VP of global scientific affairs?Kimberly Banks?will explore how?liquid biopsy testing can accelerate drug development by enhancing patient enrollment, providing early therapy response monitoring, and expediting study evaluation. Register today: https://bit.ly/3YIeU2H ???Date: November 19 ???Time: 12:00pm ET

Today we announced we will present data supporting the critical role of blood-based testing in increasing overall colorectal cancer screening adherence?at the American College of Gastroenterology’s #ACG2024 this week in Philadelphia. Our chief medical officer Craig Eagle noted, “We look forward to sharing findings at the ACG meeting that support the potential of a blood-based screening option like the Shield test to improve overall screening rates among the millions of eligible individuals who may prefer a more pleasant screening option.”

We are pleased to announce that Roberto A. Mignone has joined our board of directors. Roberto's extensive expertise in healthcare and business strategy, along with his valuable perspective, will further enhance our efforts as we advance our mission to conquer cancer with data.

This month in Dallas, our MACDOERS team dedicated some time to support the Susan G. Komen 3-Day walk to end breast cancer by packing over 1,000 recovery kits for participants. ? These kits, containing healthy snacks and first aid supplies, are a small contribution to the important work being done in the fight against #BreastCancer. We're proud to help raise awareness and support those committed to a world without breast cancer.

#HLTHUSA 2024 is around the corner! Join our chief technology officer Darya Chudova this Monday for an insightful panel discussion on the transformative power of emerging technologies in early cancer detection and treatment. ? Explore HLTH USA's full agenda:?https://bit.ly/3zUJpc6